Healthcare News 9

• "Natural" and not a steriod!
• "On the fly" patient-specific alteration of antineoplastic treatment is possible
• 5HT2 Antagonists: The Next Major Class Of Sleep Medications?
• A "drug" for all seasons
• A benefit for those with CHF and (?) Hypertension
• A can of tennis balls?
• A definite plus
• A light in the darkness?
• A likely winner
• A Misleading Study on Pharmacy Reimbursement
• A new approach-side effects?
• A New DES with less efficacy but maybe a better saftey profile is on the way.
• A new race in Psoriasis
• A new tool to improve survival rates in cardiac arrest victims?
• A non-flushing niacin is good!
• A novel agent?
• A potential boon for those suffering from IBS
• A problem
• a step toward an easily accessible health record
• A user friendly femoral access closure device with a fast learning curve
• A welcome but expensive addition
• A Winner, maybe...
• Abbotts ABT-874 shows good results in Psoriasis
• Accomplia: Does it accomplish enough?
• Acquiring Haptogen Ltd - can this bring a bright future for Wyeth Pharmaceuticals ?
• Actelion (Aliof.PK) Excites the Sleep Market with a New Drug
• Actelion’s Almorexant: How Close is it to the Ideal Hypnotic Agent?
• Actelion’s Almorexant: More Hype than Hypnosis!
• Actelion's new sleep pill works on a novel mechanism
• ACTIVE ANTIDOTE CONTROL is key to safe anticoagulation
• Adequate protection via monclonal antibodies.
• Adlea focuses on pain transmitting neurons rather than the brain and should be very helpful for those who should not use opiates
• Adlea(TM) with unique mechanism of action potentially provides elderly population undergoing total hip replacement surgery safer alternative for postopertive pain relief
• Adnexus acquisition by B-M has potential, but far to early to determine
• Adolor Corp Trailblazes New Direction in Acute and Chronic Pain Management with Development of Novel Delta-Agonist Opioid
• Aggressive Diagnosis and Treatment of TIA's is Critical
• ALCON MOVING FORWARD QUICKLY WITH WAVELIGHT PURCHASE
• Alimta first line: Absolutely!!
• All plastics are not created equal, choose wisely young biomedical engineer
• Alternative benefits for an old antibiotic - minocycline
• Amrubicin (Pharmion) When it rains it poors....
• An Assessment of The Preliminary Top Line Results for The Phase II-B RGH-188 Treatmen Trial In Schizophrenia
• An expected result
• An Experiment in Therapeutic Finance!
• An important trial look for long-range efficacy and adverse effects
• An innovation!
• An interesting finding
• Analysis of Wal-Mart's Expanded $4 Generics Program
• And now for the good news
• Another "cure" for diabetes?
• Another HIV-VL assay from a company plagued with recalls
• Another ICD Related Recall - The Medtronic Fidelis ICD Lead: Increase in Fractures
• Another improvement
• Another new player (ALTY-0501) in the limited Dye Eye Market?
• Another non-invasive test replaces traditional diagnosis
• Another toy for leg ulcers, Vascular Division of University of Barcelona
• Antibodies to Avian Flu
• Anticoagulant TB-402 Data Raise Hopes but Raise Safety Concerns
• Antidepressants: A Rising Tide Does Not Lift ALL Boats
• anti-Il-8 mAbs scream more as anti-inflammatory than anti-cancer agents, but oncological applications exist.
• Antioxidant Supplements Do NOT prevent Early Macular Degeneration.
• Approval for Aclasta
• Are Generic Drugs Truly Bioequivalent to Their Brand Name Counterparts?
• Article overstates heart risk to some degree, nevertheless important
• Article's flaws put in perspective
• Atrial Fibrillation with Bisphosphonates
• Avandia Beware: When the New V.A. Acts, It is Usually Right
• Avastin & Breast Cancer: So happy together?
• Avastin (Genentech) shows potential in second line treatment of gliobastoma multiforme brain cancer
• Avastin + Chemo has + effect in Glioblastomas (GBM) in a phase II trial
• Avastin and Irinotecan prolongs survival in recurrent Glioblastoma Multiforme
• Avastin and tarceva both not very effective in metastatic renal cell carcinoma
• Avastin For Breast Cancer: A Winner
• Avastin For Glioblastoma: Too Early to Call
• Avastin nears FDA Breast Cancer decision
• Avastin, Already Used for Breast Cancer, Likely to Receive a Formal FDA Indication
• Avastin/Tarceva (Genentech) in Lung Cancer: Synergy? Maybe!
• Avastin/Tarceva (Genentech) in Renal carcinoma: So much for synergy.
• AVEO - a leader in cancer-model based drug development
• Bacterial expression may be driver
• Bad publicity for Genentech.
• Bariatric surgery may be a legitimate way to address diabetes
• Barrier Therapeutics antifungal products needed for treatment of mycotic infections in animals.
• Barrier Therapeutics study of Hyphanox (TM) for Onychomycosis: Simpler dosing but safer?
• Beating A Dead Horse
• Behavioural skills development programme with weight loss maintenance intervention programme can help weight loss
• Better options available
• Big Brother Strikes Again
• Big or little step?
• Biological Validation of Lead Compunds
• Birds, Sewage, and the Flu = Drug-resistant Virus?
• Bisphosphonates cause abnormal heartbeat:should patient continue to use it?
• Bogus
• Bone for grafting in US derives from Human sources
• BREAKING NEWS: GENETECH TO RESTRICT THE AVAILABILITY OF AVASTIN IN ORDER TO LIMIT ITS USE OVER ITS MORE EXPENSIVE FDA APPROVED MEDICINE (LUCENTIS) FOR WET MACULAR DEGENERATION
• Bristol Myers Squib back on track
• Campath or Alemtuzumab - What's In A Name
• Campath- probable incresed use? I think so.
• Can Xeloda Triumph 5-FU? Yes! Will It? That's Another Story!
• Cancer Death Rate Decrease? Don't Worry Pharma. It will not impact your bottom line.
• Capecitabine-replaces infusional 5FU?
• Cardinal Health Gets Closer to Alliance Boots
• Caveat Emptor: IBS Therapies Almost Always Work for 12 Weeks - Then What?
• CD37-SMIP- A future competitor for Rituxan?
• Ceftobiprole for Community-Acquired Pneumonia is Breakthrough in Therapy
• Celiac Disease - waiting for Alba
• Christchurch obesity prevention program in schools- can it help to reduce childhood obesity?
• Chronic Neurological Pain
• Clearly a better vaccine
• Clinical Data’s Vilazodone Hits Mark on Phase III Depression Trial
• Clinical laboratory reagents needed to guide use of Ceftobiprole in patients.
• CMS can't possibly know what is Medically preventable, only know how to prevent paying
• CMS pay for performance scam
• Collaboration is a winner for Aveo
• Combination biologics in MS
• Combo med with 2 sites of action
• Competing With Gardasil Will Be a Tough Job
• Competition is good
• Conscientious people are less likely to develop Alzheimer's disease
• Consequences Medtronic Voluntary Suspension of Leads
• Continuing in office?? He must be kidding??
• Continuing safety reported on ISIS 301012
• Correlation is not cause and effect.
• Cost an issue
• Cost is high but quality is low--why the paradox?
• COX 2's Are Not the Future! Same Issues/Same Hosts.
• COX-2's are Dead In The U.S.A.
• Credit crunch may effect healthcare financing
• Cubicin Receives Additional Indications in Europe, But Ultimate Niche Unclear
• Cubicin, a new name and use for an old antimicrobial?
• CURE ON THE WAY FOR DECREASED SEXUAL DESIRE IN WOMEN 1 in 5 HAVE REDUCED DESIRE.
• CX717: Cortex Pharmaceutical’s Ampakine Drug for ADHD Struck Down by FDA
• Death to Avandia
• Delayed availability for Comfilcon A silicone hydrogel lenses from CooperVision
• Dental Implants raising the mad cow scare issue.
• Diabetes care in partnership with disease-associated complications regulates quality of life
• Diabetes Patients Still Seek More Convenient Therapies. Pharma Isn't There Yet.
• Diabetes.....
• Did not meet endpoints
• Differences in generic and brand names causing hazards
• Different Scents Makes no Sense, While Difference in Cents Makes Most Sense
• Differentiation Agents for Solid Cancers: The Time Has Came
• Disappointing
• DNA-based HPV analysis might replace the Pap smear
• Do Adults Having Their Blood Drawn Need an Anesthetic, or an Anxiolytic?
• Do you trust the FDA?
• Doctors Making Housecalls- Free Market Medical Care at its Best!
• Donepezil (Pfizer - PFE & Esai - Esaly.PK) Revisited - Anything New?
• Dosage Guidelines
• DOV 21,947: A Triple Reuptake Inhibitor With a Favorable Metabolic Profile
• Early detection of cholesterol level can aid treatment plan
• Eczema - not innovative, but common (Healthcare)
• Elan choices in Tysabri exploitation are clearly outlined
• Eli Lilly May Dominate the Antipsychotic Market with LY2140023
• Elocalcitol Shows No Benefits Over Current Therapies for BPH
• Emergence of Dabigatran for Prevention and Treatment of Blood Clots
• Erbitux for lung cancer: Is there meaningful clinical Benefit???
• ERBITUX in LUNG CANCER ( What is the future?)
• Erythropoietin- The final word??
• ESA fight in the italian perspective
• Esophyx Receives FDA Approval after Three Surgeries (Healthcare)
• Eventually, This Drug Will Be Banned
• EVISTA - the First for Breast Cancer Prevention and Osteoporosis Treatment..BUT
• Evista dual benefit
• Evotec: happy dreams?: TOO EARLY TO TELL
• Excellent foray into untapped field of Online Medical Records
• Excellent, reliable study
• Exciting Prospect for Alternative Treatment of COPD and asthma
• Exit Exubera
• Expected
• Experimental DNA Vaccine Treatment For MS
• Exubera - approvable is no longer reimbursable
• Exubera in a European study
• Exubera: To Little , Too Late
• Failed stomatitis biological dramatiizes simplicity over "super-science".
• Favorable Safety Data on New Anti-Obesity Drug
• FDA Approval Of FluMist For Use In Young Children Boon For MedImmune
• FDA approves a new chemotherapy drug called Ixempra to sell in the USA
• Fentanyl: Neglect on the likelihood of a perturbed metabolism
• Fentora not for beginners
• Fibromyalgia as a dysfunction of the somato-sensory and autonomic nervous system
• Finally! Rationality Returns To Psychiatric Treatment
• First-Line CAMPATH for CLL: Wide Use Unlikely
• Flouride may--or may not--come from many sources.
• FluMist add-on approval makes toddlers the ideal target market
• Fluorosis-stained Teeth are Still Preferable to Cavities; Perhaps Supplementation Guidelines Might Change in Future
• For persistent back pain treatment, call a specialist
• Fracture Reductions Save Grandma!
• Future of Rheumatoid arthritis.
• Future Treatment Of Back Pain, A Brief Synopsis
• Galvus Approved in Europe
• Galvus, Another DPP-4 Inhibitor on the Horizon (Healthcare, Novartis)
• Gardasil has advantages over Cervarix
• Genasense has limited role, if any, in melanoma treatment
• Genasense treatment for metastatic melanoma is revived, has significant potential for regulatory approval
• Genasense: If at First You Don't Succeed Try, Try Again
• Genasense: Everything Old Becomes New Again.....
• Gene therapy for RA
• Genentech (DNA) is losing Credibilty among Retina Specialists for Macular Degeneration.
• Genentech (DNA) may win the Battle but could Lose the War in Macular Degeneration.
• Genentech MUST take the stance it has - both legally and fiscally
• Generic Coreg
• Genmab's HuMax-EGFr A good study but......
• Genomics, it's time is coming
• GlaxoSmithKline's Rotarix(R) Could Be co-administered with routine infant vaccines recommended in the U.S. subject to the FDA approval
• Gloomy US future for Nobel Biocare
• Glucagon Receptor Antagonist - another weapon in our fight against Diabetes (Healthcare)
• Glufosfamide has no activity in recrrent small lung cancer
• Glufosfamide in "sensitive" small cell lung carcinoma (SCLCA): Back to the drawing board.
• Good Idea
• Good news but why gene therapy?
• Good news for TB
• Good or bad
• Good practice
• Good start if needed
• Government Nonsense, Again
• Great as long as data is unbiased.
• great but with a catch
• GReat idea, but unanswered questions remain
• Great if side effects not an issue
• Great potential
• Great relief for patient and parents
• Great to have new antibiotic against C. diff; not enough data to know if this one is it.
• GSK and Astra-Zeneca to have big losses in marketshare with generic carvedilol on market
• Has this Court Opened Pandora's Box for Physicians?
• HCV 796 Data
• HIGH BLOOD PRESSURE CASES RISING IN USA AND SO MAY GLAUCOMA
• HIV vaccines - time to face the hard reality ?
• Hope for Lupus Nephritis?
• House calls fulfill the needs of a narrow niche segment in the health care market
• House Calls: Consumer Directed Health Care's Child
• How do you differentiate between a good idea and revival of off-patent pharmaceuticals
• how much benefit?
• HPV test more accurate than Pap smear
• Hugh delay in prescription appeared to make the statistical difference
• HuMax not maximizing its potential
• HuMax-"Inflam"- Greatest potential is for inflammatory disorders
• HuMax-EGFr for Head and Neck Cancer: Is the Trial Right?
• Hycamptin (topotecan, GSK) an option for small cell lung cancer?
• Hype vs. Research in Reimbursement Policy
• I Think A Black Box Warning Will Come Soon
• I Would Hold Off Until Clinical Studies Have Been Done
• Ibuprofen Can Enhance Longevity And Quality Of Life For Children With Cystic Fibrosis
• IgG4 unhinged
• IL-1: Here we go again
• IMA901, another in a long line of drugs for renal cancer. Join the club (at the back of the line)
• IMC-A12- Even a blind pig gets a truffle some of the time....
• Immediate Workup of Transient Ischemic Attacks - a Mecial, Ethical and Health-economic Must
• Implications for use of Galvus in the U.S. after European approval is granted
• Important step forward in head and neck cancer patients
• Including people with atopic dermatosis in clinical trial for IMVAMUNE(R) Smallpox Vaccine
• Indian Pharmaceutical Manufacturers
• inhaled insulin
• Initial Avastin data interesting
• Innovative Preventive Pulmonary Therapy Offers Promise of Increased Longevity for Young Cystic Fibrosis Patients
• Interesting Approach to the Lucrative Dry Eye Market
• Interesting peptide antibiotic with cidal activity, but potential toxic side effects on eukaryotic cells in vitro
• Interesting pre-clinical data to employ in establishment of an effective cancer vaccine
• Interesting!
• Interpreting Preliminary Phase II-B Results for Forest Labs and Gedeon Richter’s RGH-188 in Schizophrenia Treatment
• Intriguing, and not just for travelers
• Inurance reimbursement for MWL body contouring
• Investigational Multiple Sclerosis Vaccine Demonstrates Safety and Hints at Efficacy
• IOMAI VACCINE
• Is it a serious matter needed to be acknoweledged by physicians?
• IS Actos a better drug? It appers at least safer.
• Is CYT645 a Potential Treatment for Osteoporosis: Who Could Possibly Know?
• Is the Betterment of Diabetes just a Weight-loss Phenomenon?
• Is the Vitamin D receptor Important in Pancreatic CA?
• It's About Time
• IV ZYFLO- GREAT POTENTIAL IN ER, BUT WILL THEY MARKET IT WELL?
• Ixempra. A hit for BMS
• Ixempra: First approved epithelone in refractory advanced breast cancer
• J&J's Stent Might be Better than Boston Sci's, but not Better than a Plain Old Stent
• Johnson & Johnson and Dapoxetine
• Junk Science Study
• Just another example of "boutique medicine"
• Just How Effective Will Orexigen’s Contrave Be As An Obesity Treatment
• Just one of a thousand other anti-cancer drugs entering into human studies
• Just part of the vaccine development process
• Know Thy Patient before You Leap to Conclusions
• Laboratory animals would provide a good model for testing new antibacterial for C. difficile.
• Lessons for Product Profile Creation
• Lessons to Be Learned: Farewell to Exubera
• Let's all exhale
• Let's Get Personal
• Lilly has great product pipe line for Schizophrenia and other Psychiatric Disorders
• Lilly is taking its products, Zyprexa® (olanzapine) and Symbyax®, in the right direction to help people with mental illness.
• Lilly's Evista: New Indication is a Plus, but New Warning is a Bigger Minus
• Lily’s Glutumate Modulator ---Very Exciting Prospect
• Lipodissolve - Hight Potential for Success but Needs More Research (Healthcare)
• Lipodissolve is very frightening.
• Local biologic non-systemic long-term anagesia a potential novel breakthrough.
• Lower safer dose of Soma approved by FDA
• Lundbeck and anticancer applications
• Lundbeck’s “Serotonin Modulator and Stimulator” Lu AA21004: How Novel? How Good?
• Lupin acquisition in Japan a positive
• LY2140023: Eli Lilly’s Investigational Antipsychotic Already Shows Promise And There Be More Good News To Come.
• Managing Managed Health Care
• Marvelous capitalist move
• Medicaid Will Have To Adopt New Standards And "Copy" Medicare
• Medical Costs Continue to Rise: It's Time to Face the Hard Facts
• Medicinal uses of violet
• Medtronic - the new Guidant?
• Menicon Releases New Silicone Hydrogel Lens (PremiO) to Contact Lens Market
• Microsoft Made Money, will they Make Money in Medicine?
• Microsoft's HealthVault: Putting Medical Information on the Web Offers Great Promise and Great Risk
• Miglustat (Actelion) enters Phase IIa trials as a corrector of DF508
• Misuse Of Fentora Cancer Pain Drug: FDA warning?
• Mixing and Matching of IOLs Shows Strengths, Weaknesses
• Molecular Diagnostics Targets Chemotherapy
• Monthly is good
• More Consolidation in the Oncology Channel
• More in vitro testing of Ortavancin is needed to prove antibacterial activity against a wider range of bacterial pathogens.
• More problems will arise
• Most US babies are at risk of too much FLUORIDE causing fluorosis
• Moving Forward With Stem Cell Technology
• MRSA kills more Americans annually than HIV
• MRSA Me!
• MRSA media attention may spur legislation and market growth
• MT103: Anti-CD19 Therapy for ALL- Can This Succeed Where Others Failed
• Needs to be compared to EVISTA.
• NEJM Study BRAC1/BRAC2 Carriers
• Neuronal effect of epo established but still highly risky
• Neuroprotection is the Key in Glaucoma Treatment
• New Concerns for Echocardiography Micro-bubble Contrast Agent Safety
• NEW DIRECTIONS IN GLAUCOMA THERAPY/RESERACH FOR FUTURE
• New Dose For Old Drug
• New drug for superficial bladder cancer with better perspectives as the actual standards? Study design will be the most important aspect to get an approval for EOquin from Spectrum Pharmaceuticals.
• New findings for genes causing Rheumatoid Arthritis
• New medicare regulations might result in better care, but at what cost?
• New Osteoporosis Drug Reduces Mortality after Hip Fracture without increase in Cardiovascular Events
• New study design makes sense, but beware of increased toxicity
• Nice to see another choice for HPV vaccine
• Nice to see the approved age range getting larger
• Nice, but will it make a clinical difference?
• NO Effect from Wyeth Pharmaceuticals Acquisition of Haptogen Ltd.
• No future for NXY-059
• no go
• Non-Inferiority Studies: What do the numbers mean, how does the FDA interpret them?
• Non-Parenteral Therapeutic Protein Formulations Allow Further Expansion of Biotechnology Products
• Northfield Labs to Push for "Priority Review" of its PolyHeme Blood Substitute
• Not a major impact in the long run
• Not so impressive
• Not sure
• Novartis and others beware!
• Novartis Pharmaceuticals Canada, Inc withdraws Prexige, Australia follows
• Novartis's Reclast: Be Careful How You Read the Numbers
• Novel agent lowers LDL with acceptable side effects.
• NSF (Nephrogenic Systemic Fibrosis) - Gadoxetic Acid (Primovist)
• Nu206: Nice rationale , but will it translate to clinical benefit??
• Nursing Homes Owned by Private Equity Firms Worse in Quality?
• Observational comment - too much flouride cannot be good for babies teeth
• Ofatumumab, Rituxan Competition? When Pigs Fly?
• Old News, Rising Medical Costs
• OMEGA 3 FATTY ACIDS CAN HOLD PROMISE IN TREAMENT OF MANY EYE DISEASES
• Once a month Actonel
• Oral Hycamtin a Step Forward in Treatment of Relapsed Small Cell Lung Cancer
• Oral is clearly easier and better.
• Overprescribing Tamiflu??
• Pain has not killed anyone
• Painkiller Problem Is Real
• Pancreatic Carcinoma: any future for Asentar?
• Patients should BLOOM on this regimen of combined behavioral and pharmacotherapy
• PDL BioPharma is having a garage sale, reserve parking with Merrill Lynch & Co.
• PDL- humanization a commodity, antibodies require big investment
• PDL tries to sell iteself
• Pemetrexed (ALIMTA) Appropriate First LIne Therapy for Lung Cancer
• Peramavir looks to have a promising future (Healthcare, BioCryst)
• Pfizer (PFE-N) Reinvents and then Opens a New Pandora's Box
• Pfizer abandons exubera
• Pfizer and patients should benefit from the results of this study of Aricept
• Pfizer HIV drug: Approval from Europe
• Pfizer Learns a Valuable - and Expensive - Lesson
• Pfizer Stumbles.....but the concept of non-injectable insulin is a good one!
• Pfizer's UK Distribution Plan in Trouble
• Pharmaceutical Companies, Hospitals and Physicians may be in for a rude awakening
• Pharmacogenomic Strategies: It's time is coming!!
• Physician house calls
• Physician House Calls- A potential major trend in the health care industry
• Pixanthrone. Different Efficacy than Mitoxanthrone?
• Pixantrone: Just another Anthracycline???
• Plastic Surgery after Bariatric Procedures - Whats cosmetic?
• Potential New Intravenous Anesthetic
• Potetial for improved adherence
• Preventing recurrence of strokes through fast assessment and treatment- hope for patients?
• Prevention as the Solution
• Procrit & Aranesp: Further damage?
• Products to round out St. Jude's Product Line
• Profit making move - Indian drug maker Lupin Ltd and Kyowa Pharmaceutical Industry Co
• Quality of life versus quality of care
• Question the efficacy of this procedure
• Questions for Physio-Control Concerning the LUCUS System
• Reclast (Novartis) a Winner!!
• Reclast sounds promising (Novartis, Healthcare)
• Reconfirmation of dual-treatment for depression: a sign for hope?
• Relieva Exceeds Expectations In Recent Clinical Trial For Eczema (Atopic Dermatitis)
• Relieva results in recent clinical trial for eczema
• Remicade anti-TNF antibody reduces need for colon surgery in ulcerative colitis patients
• Restriction on Avastin distribution will add to Genenetech's bottom line.
• Revlimid (Celgene) shows + data in non 5Q minus MDS
• RFID by AT&T: Not Your Father's Phone Company
• Right Goal, Wrong Focus: Let's Stop the Pretending
• Rimonabandt ( Accomplia) a viable and an effective tool in managenent of obesity
• Risedronate (Actonel) Trial Likely to Promote a Monthly Regimen
• Risk free travel
• Rush to alternative stent materials.....justified or not?
• Safety? Safety? Safety?
• Sanofi (SNY) Gives Accomplia a Second Try - Worth It?
• SCHIP legislation vetoed by President Bush
• Screening babies for cholesterol has no scientific basis
• Screening is a Waste of Time and Money Unless There is Treatment
• Shire (SHPGY) Hits a Rough Patch with Daytrana
• Shire Takes Proactive Stance Regarding Daytrana Skin Patches
• Shire withdraws some ADHD skin patches
• Short term interventions are NOT the answer
• Siramesine, another targeted therapy for cancer?
• Smart move by Baxter
• Soma re-visited??
• Sosei (JP:4565 TSE) & Fibromyalgia: AD 337 May Prove as Frustrating as the Illness
• Stregnths and weaknesses of daptomycin use for MRSA infections
• Study design is the key
• Super Glue: Filling a Need or Needing a Filling...A New Use for Dermabond (JNJ)
• Supply Chain Security and the FDA Act of 2007
• Susceptibility to severe side effects from drug use:individual difference issues
• Taxol is generic so don't worry......
• Taxotere and H & N Cancer: So Happy Together
• Taxotere/Head & Neck Cancer: No Bump Expected
• TB-402 - the type of anticoagulant patients and physicians are looking for as a warfarin replacement
• Technological advancement to store personal medical records:Microsoft launches new web site
• Thalidomide plus standard melphalan & prednisone extends survival in Myeloma- no surprise but.....
• Thalidomide still have a role in MM patients not eligible for transplant
• The hidden culprit in fluorosis
• The implact osteoclast inhibitors on osteonecrosis
• The Lundbeck-Takeda Alliance: A Strong CNS IP/Drug Development Platform
• The Medicare straight jacket: logos over ethos.
• The mob in the pharma industry
• The new epidemic
• The Next Decade of Depression Treatment: What’s New, What’s Old, What Will Work?
• The Pipiline is not depressed!
• The Problem is Rarely the Drug Alone...
• The Quality of Care Provided to U.S. Children is not Exactly SCHIP Shape
• The Real Wal-Mart Effect
• The relief of osteoarthritis knee pain occurred due to placement of Acupuncture needle, regardless of site
• The US FDA approves FluMist (the nasal influenza vaccine) for the treatment of healthy young children between 2 and 5 years old
• There is nothing new here!
• This Could Be A Real Blockbuster
• This One Is A No-Brainer
• This treatment is unsafe and regulation is going to make it obsolete for a time
• Three obvious reasons for decreasing performance of Tracleer sales
• Too much fluoride also means brittle bone.
• Too much unknown right now
• Totect: Very effective drug with very little use!!!!
• TPI 287: Early phase trial with good patient numbers and rational endpoints
• Transfusion Transformation ?
• Treating Adolescent Depression
• Treating Obesity is not Like Taking out the Appendix
• Treatment of Sleep Disorders
• triple therapy study design flawed
• Trubion/Wyeth's new drug for RA
• Turning and turning and back to ground zero
• Unclear if we will ever have a vaccine
• Update to Zyprexa and Symbyax Label - Expect No Big Change to Prescribing Habits
• Usability of IgG4 depends upon
• Use of injectable zileuton may not be a panacea for asthma
• Using ASP History to Evaluate AMP's Impact
• Using New Antibiotic Drug Combo the treatment time for Tuberculosis could be reduced
• Vaccine against E. Coli traveller's diarrhea
• vaccine for metastatic renal cancer
• Vanda"s Iloperidone: Lemonade or Lemon
• Vanda’s Iloperidone: A Genetically Targeted Pharmacotherapy for Schizoprenia
• Vandetanib- A "Second" Line VEGF Inhibitor
• Velcade First Line Therapy? Some Will Love it.....
• Velcade for frontline MM: Mraket forces will dictate use.
• Very good idea.
• WalMart Expansion of $4 generics
• Wal-Mart's Gain is not Walgreen's Pain
• We know we can do better
• Weak meta-analysis study and reactionary
• Well written article
• Wellcare Continues Free Generic Drug Plans for Medicare Part D
• What about Micrabuminuria?
• What are we treating?
• What Effect Will The Removal Of CFC Inhalers Have On The Health Care Market?
• What this means for the present course and future of the program.
• What's Behind the Almost Tripling in Serious Adverse Drug Events?
• When doing 'nothing' is the right thing to do
• Where goes the field of Cardiac Diagnosis and treatment?
• Who is going to take care of the patient with complication after surgery abroad ?
• Why inject?
• Why screen if we are not going to use the findings in any meaningful way?
• Will AMP be used to solve perceived Part D problems?
• Will this be the Golden Spike Uniting all Competing Approaches to Quality Measurement?
• Words of wisdom - let it be
• Worldwide Market for Lunivia (eszopiclone) Uncertain
• Wyeth's Acquisition of Haptogen Will Enhance Their Pipeline, But The Real Test is Whether This Will Lead to More Approved Therapies
• Wyeth's Bazedoxifene in osteoporosis
• Xeloda Suplants 5FU
• You look Malvelous...who cares how you feel
• Zyprexa's Effect on Lipids, Sugar, and Weight Gain